Cellarity

Artificial intelligence was more than a buzzword in 2024; it shaped pharmaceutical industry investments throughout the year, with multiple billion-dollar partnerships and acquisitions across the drug

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Eli Lilly and Company and Novo Nordisk A/S have been expanding the indications of their drugs approved to treat obesity to add to the already huge income such products have generated. Meanwhile, it

Eli Lilly and Company and Novo Nordisk A/S have been expanding the indications for their drugs first approved to treat obesity to add to the already huge income such products have generated. Meanwh